Suggestions

NRC · NASDAQ

NRC HEALTH

Private beta

Sector unavailable · Industry unavailable

$21.12

-0.66%

Close on Sep 11, 2026

Insufficient Data

Updated date unavailable

Long-term research evidence only. No price targets, no trading signals, no recommendations.

Investment Report Card

NRC HEALTH

Sector unavailable · Data confidence partial

No Pro Investor Score today

SCORE_PENDING_OWNERSHIP

Risk Intelligence

Core Model

Not Available

Insufficient Data

How strong and defensively sound is the company?

This reading is not available for this company yet.

Long-Term Potential

Research Model

Not Available

Insufficient Data

Does the business have the characteristics needed to create value over many years?

This reading is not available for this company yet.

Fundamental Momentum

Research Model

Not Available

Insufficient Data

Is the underlying business getting stronger or weaker?

This reading is not available for this company yet.

Ownership Intelligence

Supplemental Intelligence

Not Available

Insufficient Coverage

What are important owners actually doing?

This reading is not available for this company yet.

Valuation Intelligence

Research Model
D

40 / 100

Elevated

Is today's price reasonable?

Weaker than most covered companies on this measure — and valuation is researched separately from the Suggested Investment Score.

Capital Returns Intelligence

Research Model
D+

54 / 100

Moderate Capital Returns

How effectively does the company reward shareholders?

Weaker than most covered companies on this measure — and capital returns are researched separately from the Suggested Investment Score.

Why it stands out

No strengthening evidence is recorded in today's readings.

What holds it back

  • Ownership evidence is incomplete and should not be read as comprehensive.
  • Elevated valuation: the current market price reflects a premium to this company's historical valuation and comparable companies (Valuation Intelligence 40 out of 100, Elevated).

Long-term view

Long-Term Potential is not available for this company, so no long-term reading is shown.

Ownership view

No disclosed ownership reading is available at the required confidence, so ownership is left blank rather than estimated.

Valuation view

NRC HEALTH reads 40 out of 100 on Valuation Intelligence, recorded as Elevated. The stock currently trades above most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value. Valuation Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.

Capital returns view

NRC HEALTH reads 54 out of 100 on Capital Returns Intelligence (Moderate Capital Returns), reflecting a dividend paid for 13 consecutive years and a share count falling about 3.0% a year. Capital Returns Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.

What changed

No meaningful recorded changes in the stored history.

Risk Intelligence is a core model, Long-Term Potential, Fundamental Momentum, Valuation Intelligence and Capital Returns Intelligence are research models, and Ownership Intelligence is supplemental descriptive evidence. Valuation Intelligence and Capital Returns Intelligence each contribute 0% to the Suggested Investment Score. Nothing here is a recommendation.

Compare NRC with other companies

Research Collections

This company does not currently satisfy any collection rule. That is a stored research result, not a judgement about the business.

Browse collections

60-Second Brief

Too few stored readings exist for this company to summarise honestly.

Composite discovery model

Pro Investor Score

Pro Investor Score™

Score Pending — Insufficient Ownership Coverage

A composite score is only published when every required input is available for this company. Nothing is estimated to fill a gap, and exclusion from the ranking is not a sell instruction.

COMPOSITE DISCOVERY MODEL — RESEARCH STAGE · Ranking updated September 12, 2026

Researched separately

Valuation Intelligence 40 · Elevated

RESEARCH MODEL

Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.

Researched separately

Capital Returns Intelligence 54 · Moderate Capital Returns

RESEARCH MODEL

Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.

Why this company scores the way it does

This company does not currently hold a stored Pro Investor Score, so no contribution breakdown can be shown.

Pro Investor Intelligence™

Reported by insiders, large shareholders and professional funds. Shown beside our research, never blended into it.

Loading professional-investor activity…

Stored snapshots only

What changed

Research-score history available since September 2026.

Stored research history does not yet cover a full 30 days comparison for this company.

A change is reported as meaningful at 8 score points, 5 rank places, or any change of research classification. Nothing here is a recommendation to buy or sell.

Learn the metrics on this page

Plain-English definitions, with the formula and the limitations of each measure.

Fifth research lens · outside the score

Valuation Intelligence

Valuation Intelligence

Is today's price reasonable?

Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.

40/ 100

Elevated

RESEARCH MODEL
Excellent coverage

Compared with its history

54

Reasonable

Is this company expensive or inexpensive compared with its own history?

Compared with peers

17

Expensive

How expensive is this stock compared with similar companies?

Earnings & cash flow

47

Elevated

How much financial output does an investor receive relative to the price paid?

Growth-adjusted

40

Elevated

Does the company's growth help justify the valuation investors are paying?

NRC HEALTH reads 40 out of 100 on Valuation Intelligence, recorded as Elevated. The stock currently trades above most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value.

Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026

Valuation history

Stored readings only. The dashed line is this company's own median for the selected measure.

Only one stored valuation reading exists so far, so there is nothing to chart yet. Valuation history builds forward from activation rather than being reconstructed.

Current P/E 79.7x · own median 35.4x · peer median 32.6x

Valuation is inherently uncertain. A stock that appears inexpensive can continue falling, and a stock that appears expensive can continue rising. Valuation Intelligence provides context about the price investors are paying — it does not predict short-term market movements, and it never produces a fair value, a price target or a buy or sell range. Model VALUATION_INTELLIGENCE_V1.

Sixth research lens · outside the score

Capital Returns Intelligence

Capital Returns Intelligence

How effectively does the company reward shareholders?

Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.

54/ 100

Moderate Capital Returns

RESEARCH MODEL
Excellent coverage

Dividend Quality

41

Limited Capital Returns

Dividend reliability

Buyback Effectiveness

77

Strong Capital Returns

Do buybacks actually reduce shares?

Dilution Control

78

Strong Capital Returns

Is your ownership share protected?

Capital Return Sustainability

2

Limited Capital Returns

Can the cash flow support it?

Shareholder Yield

83

Exceptional Capital Returns

Cash returned versus company value

NRC HEALTH reads 54 out of 100 on Capital Returns Intelligence (Moderate Capital Returns), reflecting a dividend paid for 13 consecutive years and a share count falling about 3.0% a year.

Distributions coincided with rising debt over this period, so part of the cash returned was not funded by the cash the business generated.

How returned cash was used

Dividends $12.71M · net repurchases $18.71M · total returned $31.41M · 145% of free cash flow

Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026

Capital returns history

Stored readings only. History builds forward from activation rather than being reconstructed.

Only one stored reading exists for this measure so far, so there is nothing to chart yet.

Why higher yield isn't always better

A very high dividend yield may reflect a falling share price or an unsustainable payout. Capital Returns Intelligence emphasizes consistency and sustainability rather than simply rewarding the highest yield.

Why buybacks can be misleading

Announced or gross buyback spending does not always mean shareholders are gaining ownership. Companies can simultaneously issue shares through employee compensation or acquisitions. Suggested Investments therefore considers actual share-count changes alongside repurchase spending.

What these terms mean
Dividend Yield
The annual dividend relative to the current share price.
Payout Ratio
The share of company earnings used to pay dividends.
Free Cash Flow Payout
How much of the company's available cash is being used for dividends.
Share Repurchases
When a company buys back its own stock.
Dilution
When the number of shares increases, reducing each existing share's percentage ownership of the company.
Shareholder Yield
A combined view of dividends and net share repurchases relative to the company's market value.

Capital Returns Intelligence describes how a company returns capital to shareholders. It is not a measure of stock-price performance, it does not predict future returns, and a strong reading is never a recommendation to buy. Dividends and repurchases can be reduced or stopped at any time. Model CAPITAL_RETURNS_INTELLIGENCE_V1, contributing 0% to the Pro Investor Score.

Stored daily snapshots only

Ranking history

Stored Suggested Investment ranking history
TodayNot rankedNo stored score
30 days agoNot rankedNo stored score
90 days agoNot rankedNo stored score
First suggestedNot yet suggested
Highest rankNot ranked

In the company’s own words

What this company does

Certain matters discussed in this Annual Report on Form 10-K are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can generally be identified as such because the context of the statement includes phrases such as National Research Corporation, doing business as NRC Health ("NRC Health," the "Company," "we," "our," "us" or similar terms), "believes," "expects," "may," "could," "anticipates," "estimates," "plans," "creates," "intends," or the use of words such as "would," "will," "may," "could," "goal," "focus," or "should," or other words of similar import. Similarly, statements that describe our future plans, objectives or goals are also forward-looking statements. In this Annual Report on Form 10-K, statements regarding the value and utility of, and market demand for, our service offerings, future opportunities for growth with respect to new and existing customers, our future ability to compete and the types of firms with which we will compete, future consolidation in the healthcare industry, future adequacy of our liquidity sources, future revenue sources, future revenue, expenses, and margins, future revenue estimates used to calculate total recurring contract value, the expected impact of economic factors, including interest rates and inflation, future capital expenditures, and the timing, amount, and sources of cash to fund such capital expenditures, future stock repurchases and dividends, the expected impact of pending claims and contingencies, the future outcome of uncertain tax positions, our future use of owned and leased real property, and the expected impact of global conflicts, among others, are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties which could cause actual results or outcomes to differ materially from those currently anticipated. Factors that could affect actual results or outcomes include, without limitation, the following factors:

The possibility of non-renewal of our customer service contracts, reductions in services purchased or prices, and failure to retain key customers;

Our ability to compete in our markets, which are highly competitive with new market entrants, subject to consolidation among existing competitors, and the possibility of increased price pressure and expenses;

The possibility that our acquisitions and partnerships do not achieve the increased demand/profitability expected;

Quoted from the business section of this company’s 10-K filed March 5, 2026. Read the filing

Four distinct intelligence areas

The IA view

Risk Intelligence

Production core

52

Fundamentally Qualified

No prior period to compare

Business Quality qualification score from the locked IA Defensive Research Core. Price Risk stays a separate category and is never blended in.

As of Sep 11, 2026

Long-Term Potential

Research model

36

Weak Compounder

No prior period to compare

Durable business economics and reinvestment characteristics. Independent external validation is pending.

As of Sep 11, 2026

Fundamental Momentum

Research model

41

Deteriorating

No prior period to compare

Direction and breadth of change in underlying business fundamentals. Not a price-momentum signal.

As of Sep 11, 2026

Elite Investor Activity

Supplemental

Insufficient Data

No prior period to compare

No tracked manager filings mapped to this company.

Intelligence history

Not enough stored history to chart NRC yet. A company needs at least two published research or ownership periods before a trend can be shown.

Share price

NRC price history

Closing prices adjusted for splits and dividends. Past prices do not indicate future results.

6M change
+30.2%
1Y change
+34.9%
3Y change
-48.0%
5Y change
-49.8%
Max change
-63.0%

Last stored close $21.12 · +34.9% over the selected range · 52 sessions shown

Balanced evidence

Why IA likes it

  • No positive evidence is available under the current coverage.

Risk and uncertainty

What IA doesn’t like

  • Ownership evidence is incomplete and should not be read as comprehensive.

What would change our view

  • Business Quality falling below the frozen qualification threshold.
  • Price Risk moving to a less favorable category.
  • A sustained reversal in the Fundamental Momentum research evidence.
  • New material public ownership disclosures.

Public filings · descriptive only

Elite Investor Activity

Reporting holders

New holders

Increasing

Reducing

Exiting

Coverage

Insufficient

Insufficient Coverage · Report period unavailable · Public date unavailable

ManagerChangePortfolio weightRankDisclosed

Insufficient high-confidence manager coverage.

Objective stored changes

What changed

No qualifying changes are recorded for this company in the stored research and filing history.

Ownership timeline

No high-confidence public ownership events are available.

General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.